Literature DB >> 21521926

Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome.

Kiichiro Hiraishi1, Takanobu Yoshimoto, Kyoichiro Tsuchiya, Isao Minami, Masaru Doi, Hajime Izumiyama, Hironobu Sasano, Yukio Hirata.   

Abstract

Primary aldosteronism (PA), an autonomous aldosterone hypersecretion from adrenal adenoma and/or hyperplasia, and subclinical Cushing syndrome (SCS), a mild but autonomous cortisol hypersecretion from adrenal adenoma without signs or symptoms of Cuhing's syndrome, are now well-recognized clinical entities of adrenal incidentaloma. However, the clinicopathological features of PA associated with SCS (PA/SCS) remain unknown. The present study was undertaken to study the prevalence of PA/SCS among PA patients diagnosed at our institute, and characterize their clinicopathlogical features. The prevalence of PA/SCS was 8 of 38 PA patients (21%) studied. These 8 PA/SCS patients were significantly older and had larger tumor, higher serum potassium levels, lower basal plasma levels of aldosterone, ACTH and DHEA-S as well as lower response of aldosterone after ACTH stimulation than those in 12 patients with aldosterone-producing adenoma without hypercortisolism. All 8 PA/SCS patients showed unilateral uptake by adrenal scintigraphy at the ipsilateral side, whereas the laterality of aldosterone hypersecretion as determined by adrenal venous sampling varied from ipsilateral (3), contralateral (2), and bilateral side (2). 6 PA/SCS patinets who underwent adrenalectomy required hydrocortisone replacement postoperatively. Histopathological analysis of the resected adrenal tumors from 5 PA/SCS patients revealed a single adenoma in 3, and double adenomas in 2, with varying degrees of positive immunoreactivities for steroidgenic enzymes (3β-HSD, P450(C17)) by immunohistochemical study as well as CYP11B2 mRNA expression as measured by real-time RT-PCR. In conclusion, PA/SCS consists of a variety of adrenal pathologies so that therapeutic approach differs depending on the disease subtype. ©The Japan Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521926     DOI: 10.1507/endocrj.k10e-402

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  26 in total

1.  Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series.

Authors:  Francesco Fallo; Isabella Castellano; Celso E Gomez-Sanchez; Yara Rhayem; Catia Pilon; Valentina Vicennati; Donatella Santini; Valeria Maffeis; Ambrogio Fassina; Paolo Mulatero; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

2.  Primary aldosteronism associated with subclinical Cushing syndrome.

Authors:  K Fujimoto; S Honjo; H Tatsuoka; Y Hamamoto; Y Kawasaki; A Matsuoka; H Ikeda; Y Wada; H Sasano; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

3.  Hypertension Cure Following Laparoscopic Adrenalectomy for Hyperaldosteronism is not Universal: Trends Over Two Decades.

Authors:  Takeshi Namekawa; Takanobu Utsumi; Tomoaki Tanaka; Mayuko Kaga; Hidekazu Nagano; Takashi Kono; Koji Kawamura; Naoto Kamiya; Takashi Imamoto; Hiroyoshi Suzuki; Tomohiko Ichikawa
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

4.  Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism.

Authors:  Fumitoshi Satoh; Ryo Morimoto; Yoshikiyo Ono; Yoshitsugu Iwakura; Kei Omata; Masataka Kudo; Kei Takase; Kazumasa Seiji; Hidehiko Sasamoto; Seijiro Honma; Mitsunobu Okuyama; Kouwa Yamashita; Celso E Gomez-Sanchez; William E Rainey; Yoichi Arai; Hironobu Sasano; Yasuhiro Nakamura; Sadayoshi Ito
Journal:  Hypertension       Date:  2015-03-16       Impact factor: 10.190

5.  Development of a novel nomogram to predict hypertension cure after laparoscopic adrenalectomy in patients with primary aldosteronism.

Authors:  Takanobu Utsumi; Naoto Kamiya; Takumi Endo; Masashi Yano; Shuichi Kamijima; Koji Kawamura; Takashi Imamoto; Yukio Naya; Tomohiko Ichikawa; Hiroyoshi Suzuki
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

6.  Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids.

Authors:  Vivienne Yoon; Aliya Heyliger; Takashi Maekawa; Hironobu Sasano; Kelley Carrick; Stacey Woodruff; Jennifer Rabaglia; Richard J Auchus; Hans K Ghayee
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-09-23

Review 7.  New Advances in the Diagnostic Workup of Primary Aldosteronism.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  J Endocr Soc       Date:  2017-01-27

8.  Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism.

Authors:  Wiebke Arlt; Katharina Lang; Alice J Sitch; Anna S Dietz; Yara Rhayem; Irina Bancos; Annette Feuchtinger; Vasileios Chortis; Lorna C Gilligan; Philippe Ludwig; Anna Riester; Evelyn Asbach; Beverly A Hughes; Donna M O'Neil; Martin Bidlingmaier; Jeremy W Tomlinson; Zaki K Hassan-Smith; D Aled Rees; Christian Adolf; Stefanie Hahner; Marcus Quinkler; Tanja Dekkers; Jaap Deinum; Michael Biehl; Brian G Keevil; Cedric Hl Shackleton; Jonathan J Deeks; Axel K Walch; Felix Beuschlein; Martin Reincke
Journal:  JCI Insight       Date:  2017-04-20

9.  Renin angiotensin aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism.

Authors:  Bertille Elodie Edinga-Melenge; Vicky J Ama Moor; Jobert Richie N Nansseu; Romance Nguetse Djoumessi; Michel K Mengnjo; Jean-Claude Katte; Jean Jacques N Noubiap; Eugene Sobngwi
Journal:  JRSM Cardiovasc Dis       Date:  2017-02-01

10.  Bilateral Adrenocortical Masses Producing Aldosterone and Cortisol Independently.

Authors:  Seung Eun Lee; Jae Hyeon Kim; You Bin Lee; Hyeri Seok; In Seub Shin; Yeong Hee Eun; Jung Han Kim; Young Lyun Oh
Journal:  Endocrinol Metab (Seoul)       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.